Identification of thyroid carcinoma related genes with mRMR and shortest path approaches

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Xu, Yaping ^a   Deng, Yue ^a   Ji, Zhenhua ^a   Liu, Haibin ^a   Liu, Yueyang ^a   Peng, Hu ^a   Wu, Jian ^a   Fan, Jingping ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MISCELLANEOUS RNA; PROTEIN BCL 2; RNA; TRANSCRIPTOME; UNCLASSIFIED DRUG; MESSENGER RNA; TUMOR PROTEIN;

ANAPLASTIC CARCINOMA; ARTICLE; BCL2 GENE; CANCER GROWTH; CONTROLLED STUDY; DLG2 GENE; GENE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC DATABASE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; ID4 GENE; INCREMENTAL FEATURE SELECTION; MACHINE LEARNING; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MAXIMUM RELEVANCE MINIMUM REDUNDANCY ALGORITHM; MOLECULAR DYNAMICS; MRPS31 GENE; MY01B GENE; PPP6C GENE; PRKCQ GENE; PROTEIN PROTEIN INTERACTION; RASAL2 GENE; SHORTEST PATH ALGORITHM; THYROID CARCINOMA; THYROID PAPILLARY CARCINOMA; VALIDATION PROCESS; ZBTB5 GENE; ALGORITHM; CARCINOMA; CHEMISTRY; DNA MICROARRAY; GENETICS; PAPILLARY CARCINOMA; THYROID GLAND; THYROID TUMOR; TISSUE MICROARRAY; TUMOR GENE;

ALGORITHMS; CARCINOMA; CARCINOMA, PAPILLARY; GENES, NEOPLASM; GENETIC ASSOCIATION STUDIES; HUMANS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN INTERACTION MAPS; RNA, MESSENGER; RNA, NEOPLASM; THYROID GLAND; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS; TRANSCRIPTOME;

EID: 84899557789     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094022     Document Type: Article

References (38)

1. Ain KB (1999) Anaplastic thyroid carcinoma: A therapeutic challenge. Seminars in Surgical Oncology 16: 64-69.
2. Smallridge RC, Marlow LA, Copland JA (2009) Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocrine-Related Cancer 16: 17-44.
3. Montero-Conde C, Martin-Campos JM, Lerma E, Gimenez G, Martinez-Guitarte JL, et al. (2008) Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene 27: 1554-1561. (Pubitemid 351347876)
4. Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, et al. (2007) A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Research 67: 10148-10158. (Pubitemid 350070786)
5. Hebrant A, Dom G, Dewaele M, Andry G, Tresallet C, et al. (2012) mRNA Expression in Papillary and Anaplastic Thyroid Carcinoma: Molecular Anatomy of a Killing Switch. Plos One 7.
6. Li B-Q, Huang T, Liu L, Cai Y-D, Chou K-C (2012) Identification of Colorectal Cancer Related Genes with mRMR and Shortest Path in Protein-Protein Interaction Network. Plos One 7.
7. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, et al. (2011) The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Research 39: D561-D568.
8. Csardi G, Nepusz T (2006) The igraph software package for complex network research. InterJounal Complex Systems: 1695.
9. Peng HC, Long FH, Ding C (2005) Feature selection based on mutual information: Criteria of max-dependency, max-relevance, and min-redundancy. Ieee Transactions on Pattern Analysis and Machine Intelligence 27: 1226-1238.
10. Friedman JH, Baskett F, Shustek LJ (1975) An Algorithm for Finding Nearest Neighbors. Computers, IEEE Transactions on C-24: 1000-1006.
11. Chou K-C, Shen H-B (2006) Predicting eukaryotic protein subcellular location by fusing optimized evidence-theoretic K-Nearest Neighbor classifiers. Journal of Proteome Research 5: 1888-1897. (Pubitemid 44232701)
12. Chou K-C (2011) Some remarks on protein attribute prediction and pseudo amino acid composition. Journal of Theoretical Biology 273: 236-247.
13. Li B-Q, Hu L-L, Chen L, Feng K-Y, Cai Y-D, et al. (2012) Prediction of Protein Domain with mRMR Feature Selection and Analysis. PLoS ONE 7: e39308.
14. Ambroise C, McLachlan GJ (2002) Selection bias in gene extraction on the basis of microarray gene-expression data. Proceedings of the National Academy of Sciences of the United States of America 99: 6562-6566. (Pubitemid 34526172)
15. Kohavi R (1995) A study of cross-validation and bootstrap for accuracy estimation and model selection. Proceedings of the 14th international joint conference on Artificial intelligence- Volume 2.Montreal, Quebec, Canada: Morgan Kaufmann Publishers Inc. pp. 1137-1143.
16. Dijkstra E (1959) A note on two problems in connection with graphs. Numerische Mathematik 1: 269-271.
17. Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols 4: 44-57.
18. Cronin SJF, Penninger JM (2007) From T-cell activation signals to signaling control of anti-cancer immunity. Immunological Reviews 220: 151-168. (Pubitemid 350045570)
19. Heubner M, Wimberger P, Otterbach F, Kasimir-Bauer S, Siffert W, et al. (2009) Association of the AA genotype of the BCL2 (-938C>A) promoter polymorphism with better survival in ovarian cancer. Int J Biol Markers 24: 223-229.
20. Bachmann HS, Otterbach F, Callies R, Nuckel H, Bau M, et al. (2007) The AA genotype of the regulatory BCL2 promoter polymorphism (938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. Clin Cancer Res 13: 5790-5797. (Pubitemid 47591643)
21. Bachmann HS, Heukamp LC, Schmitz KJ, Hilburn CF, Kahl P, et al. (2011) Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma. Int J Cancer 129: 2390-2399.
22. Rossi D, Rasi S, Capello D, Gaidano G (2008) Prognostic assessment of BCL2-938C>A polymorphism in chronic lymphocytic leukemia. Blood 111: 466-468.
23. Aksoy M, Giles Y, Kapran Y, Terzioglu T, Tezelman S (2005) Expression of bcl-2 in papillary thyroid cancers and its prognostic value. Acta Chir Belg 105: 644-648. (Pubitemid 43080978)
24. Eun YG, Hong IK, Kim SK, Park HK, Kwon S, et al. (2011) A Polymorphism (rs1801018, Thr7Thr) of BCL2 is Associated with Papillary Thyroid Cancer in Korean Population. Clin Exp Otorhinolaryngol 4: 149-154.
25. Noetzel E, Veeck J, Niederacher D, Galm O, Horn F, et al. (2008) Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer 8: 154.
26. Deleu S, Savonet V, Behrends J, Dumont JE, Maenhaut C (2002) Study of gene expression in thyrotropin-stimulated thyroid cells by cDNA expression array: ID3 transcription modulating factor as an early response protein and tumor marker in thyroid carcinomas. Exp Cell Res 279: 62-70.
27. Kebebew E, Peng M, Treseler PA, Clark OH, Duh QY, et al. (2004) Id1 gene expression is up-regulated in hyperplastic and neoplastic thyroid tissue and regulates growth and differentiation in thyroid cancer cells. J Clin Endocrinol Metab 89: 6105-6111. (Pubitemid 39628422)
28. Rigolet M, Rich T, Gross-Morand MS, Molina-Gomes D, Viegas-Pequignot E, et al. (1998) cDNA cloning, tissue distribution and chromosomal localization of the human ID4 gene. DNA Res 5: 309-313. (Pubitemid 128670169)
29. Chen GG, Vlantis AC, Zeng Q, van Hasselt CA (2008) Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Curr Cancer Drug Targets 8: 367-377.
30. Fujimoto J, Hirose R, Ichigo S, Sakaguchi H, Tamaya T (1998) DNA polymorphism in B-domain of the estrogen receptor-alpha among Japanese women. Steroids 63: 146-148. (Pubitemid 28173392)
31. Lehrer SP, Schmutzler RK, Rabin JM, Schachter BS (1993) An estrogen receptor genetic polymorphism and a history of spontaneous abortion - correlation in women with estrogen receptor positive breast cancer but not in women with estrogen receptor negative breast cancer or in women without cancer. Breast Cancer Res Treat 26: 175-180. (Pubitemid 23262080)
32. Massart F, Becherini L, Gennari L, Facchini V, Genazzani AR, et al. (2001) Genotype distribution of estrogen receptor-alpha gene polymorphisms in Italian women with surgical uterine leiomyomas. Fertil Steril 75: 567-570. (Pubitemid 32175673)
33. Rebai M, Kallel I, Charfeddine S, Hamza F, Guermazi F, et al. (2009) Association of polymorphisms in estrogen and thyroid hormone receptors with thyroid cancer risk. J Recept Signal Transduct Res 29: 113-118.
34. Leeman-Neill RJ, Brenner AV, Little MP, Bogdanova TI, Hatch M, et al. (2013) RET/PTC and PAX8/PPARgamma chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. Cancer 119: 1792-1799.
35. McIver B, Grebe SK, Eberhardt NL (2004) The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Curr Drug Targets Immune Endocr Metabol Disord 4: 221-234. (Pubitemid 39199358)
36. Eberhardt NL, Grebe SK, McIver B, Reddi HV (2010) The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol 321: 50-56.
37. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, 2nd, et al. (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88: 2318-2326. (Pubitemid 36549913)
38. Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, et al. (2006) Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 25: 2304-2317.